Search Result

Results for "

ibrutinib

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) BCL6 (1) Btk (19) Eukaryotic Initiation Factor (eIF) (1) Isotope-Labeled Compounds (1) Ligands for Target Protein for PROTAC (3) MNK (1) PI3K (1) PROTAC Linkers (2) PROTACs (2) Src (1)
By Research Areas:	Cancer (24)
Click Chemistry:	PROTAC Synthesis (2) Alkynes (2)

Inhibitors & Agonists

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10997

*Ibrutinib* Maximum Cited Publications 98 Publications Verification PCI-32765	Btk Ligands for Target Protein for PROTAC	Cancer
Ibrutinib (PCI-32765) is a selective, irreversible Btk inhibitor with an IC₅₀ of 0.5 nM .

HY-43521

Ibrutinib-MPEA	Btk	Cancer
Ibrutinib-MPEA (Compound 20) is ibrutinib derivative. Ibrutinib is a covalent and irreversible inhibitor of Bruton's tyrosine kinase (BTK) that has been used to treat haematological malignancies .

HY-10997A

Ibrutinib Racemate 1 Publications Verification PCI-32765 Racemate	Btk	Cancer
Ibrutinib Racemate (PCI-32765 Racemate) is the racemate of Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor with IC₅₀ value of 0.5 nM.

HY-78727

Ibrutinib deacryloylpiperidine IBT4A	Btk	Cancer
Ibrutinib deacryloylpiperidine (IBT4A) is an impurity of Ibrutinib . Ibrutinib is a selective, irreversible Btk inhibitor with an IC₅₀ of 0.5 nM .

HY-100342

Ibrutinib-biotin 2 Publications Verification	Btk	Cancer
Ibrutinib-biotin is a probe that consists of Ibrutinib linked to biotin via a long chain linker, extracted from patent WO2014059368A1 Compound 1-5, has an IC₅₀ of 0.755-1.02 nM for BTK.

HY-10997S

Ibrutinib-d5 PCI-32765-d₅	Btk	Cancer
Ibrutinib-d₅ is a deuterium labeled Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor[1].

HY-100659

Dihydrodiol-Ibrutinib PCI-45227	Btk	Cancer
Dihydrodiol-Ibrutinib (PCI-45227) is a dihydrodiol active metabolite of Ibrutinib (HY-10997), has inhibitory activity towards BTK approximately 15 times lower than that of ibrutinib .

HY-130983

*N-piperidine Ibrutinib* hydrochloride**	Btk Ligands for Target Protein for PROTAC	Cancer
N-piperidine Ibrutinib hydrochloride (Compound 1) is a reversible Ibrutinib derivative. N-piperidine Ibrutinib hydrochloride is a potent BTK inhibitor with IC₅₀s of 51.0 and 30.7 nM for WT BTK and C481S BTK, respectively . N-piperidine Ibrutinib hydrochloride can be used as a BTK ligand in the synthesis of a series of PROTACs, such as SJF620 (HY-133137). SJF620 is a potent PROTAC BTK degrader with a DC₅₀ of 7.9 nM .

HY-136113

Ibrutinib dimer	Btk	Cancer
Ibrutinib dimer is a Dimer of Ibrutinib. Ibrutinib dimer is an impurity of Ibrutinib . Ibrutinib is a selective, irreversible Btk inhibitor with an IC₅₀ of 0.5 nM .

HY-10997R

Ibrutinib (Standard)	Btk Ligands for Target Protein for PROTAC	Cancer
Ibrutinib (Standard) is the analytical standard of Ibrutinib. This product is intended for research and analytical applications. Ibrutinib (PCI-32765) is a selective, irreversible Btk inhibitor with an IC₅₀ of 0.5 nM .

HY-100659S

*Dihydrodiol-Ibrutinib-d5* PCI-45227-d₅	Btk Isotope-Labeled Compounds	Cancer
Dihydrodiol-Ibrutinib-d5 is the deuterium labeled Dihydrodiol-Ibrutinib (HY-100659). Dihydrodiol-Ibrutinib is a dihydrodiol active metabolite of Ibrutinib (HY-10997), has inhibitory activity towards BTK approximately 15 times lower than that of ibrutinib .

HY-148585

BTK-IN-22	Btk	Cancer
BTK-IN-22 is a BTK inhibitor (IC₅₀: 0.9 nM). BTK-IN-22 also inhibits BLX and BMX with IC₅₀s of 1.4 and 1.2 nM respectively. BTK-IN-22 shows improved kinase selectivity compared to Ibrutinib (HY-10997)

HY-148594

BTK-IN-23	Btk	Cancer
BTK-IN-23 is a BTK inhibitor (IC₅₀: 12.8 nM). BTK-IN-23 also inhibits BLX and BMX with IC₅₀s of 35.6 and 5.7 nM respectively. BTK-IN-23 shows improved kinase selectivity compared to Ibrutinib (HY-10997) .

HY-15805

KIN-8194	Src Btk	Cancer
KIN-8194 is an orally active dual inhibitor of HCK and BTK, with IC₅₀ values of 0.915 and <0.495 nM, respectively. KIN-8194 impairs growth and integrin-mediated adhesion of BTKi-resistant mantle cell lymphoma (MCL). KIN-8194 overcomes ibrutinib (HY-10997) resistance with a survival benefit in TMD-8 ABC DLBCL xenografted mice .

HY-13036A

IBT6A	Btk	Cancer
IBT6A is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct . Ibrutinib is a selective, irreversible Btk inhibitor with an IC₅₀ of 0.5 nM .

HY-13036B

IBT6A hydrochloride	Btk	Cancer
IBT6A hydrochloride is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct . Ibrutinib is a selective, irreversible Btk inhibitor with an IC₅₀ of 0.5 nM .

HY-13036

(Rac)-IBT6A	Btk	Cancer
(Rac)-IBT6A is a racemate of IBT6A. IBT6A is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct . Ibrutinib is a selective, irreversible Btk inhibitor with an IC₅₀ of 0.5 nM .

HY-13036C

(Rac)-IBT6A hydrochloride	Btk	Cancer
(Rac)-IBT6A hydrochloride is a racemate of IBT6A hydrochloride. IBT6A is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct . Ibrutinib is a selective, irreversible Btk inhibitor with an IC₅₀ of 0.5 nM .

HY-150638

PI3Kδ/γ-IN-3	PI3K Apoptosis	Cancer
PI3Kδ/γ-IN-3 (Compound 58) is a potent and orally active PI3Kδ and PI3Kγ dual inhibitor with IC₅₀s of 1 nM and 16 nM, respectively. PI3Kδ/γ-IN-3 induces tumor cell apoptosis and can be used for B-cell malignancies research .

HY-163479

MNK1/2-IN-7	Eukaryotic Initiation Factor (eIF) MNK	Cancer
MNK1/2-IN-7 (compound 20j) is an orally available inhibitor of MNK1/2 with anticancer activity and hERG safety. MNK1/2-IN-7 also inhibits the phosphorylation of eIF4E, inhibiting the MNK/eIF4E signaling pathway and cancer cell proliferation. MNK1/2-IN-7 is synergistic with Ibrutinib (HY-109970) .

HY-130481

Propargyl-PEG4-acid	PROTAC Linkers	Cancer
Propargyl-PEG4-acid is a PEG-based PROTAC linker can be used in the synthesis of BTK-IAP PROTACs Ibrutinib (HY-10997)-based PROTAC 2 and an analogue PROTAC 3. PROTAC 3 causes BTK degradation with a DC₅₀ of 200 nM in THP-1 cells . Propargyl-PEG4-acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-130504

Propargyl-PEG1-acid 1 Publications Verification	PROTAC Linkers	Cancer
Propargyl-PEG1-acid is a PEG-based PROTAC linker can be used in the synthesis of BTK-CRBN PROTACs Ibrutinib(HY-10997)-based PROTAC 4 and PROTAC 5. PROTAC 5 causes the degradation of BTK and induces the degradation of CSK, LYN, and LAT2 at 10 μM . Propargyl-PEG1-acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-161989

DZ-837	PROTACs BCL6	Cancer
DZ-837 (compound 3d) is a PROTAC targeting BCL6 with a DC50 of approximately 600 nM. DZ-837 can induce cell cycle arrest and exert synergistic anticancer effects with Ibrutinib (HY-10997). DZ-837 is composed of PROTAC target protein ligand BCL6 ligand-2 (HY-161990) (red part), E3 ubiquitin ligase ligand Thalidomide-4-OH (HY-103596) (blue part), and PROTAC Linker (HY-W245803) (black part), among which the conjugate of E3 ubiquitin ligase ligand + Linker is 2-(2,6-Dioxopiperidin-3-yl)-4-((2-(2-hydroxyethoxy)ethyl)amino)isoindoline-1,3-dione (HY-W924949) ^{[1] ^.}

HY-153220

NX-2127	PROTACs Btk	Cancer
NX-2127 is a a PROTAC targeting Bruton’s Tyrosine Kinase (Btk) with oral activity. NX-2127 is composed of PROTAC target protein ligand BTK ligand 10 (HY-168302) (red part), E3 ligase ligand Thalidomide 5-fluoride (HY-W087383) (blue part) and PROTAC Linker (S)-4-(1-(Pyrrolidin-3-ylmethyl)piperidin-4-yl)aniline (HY-168303) (black part), among which the conjugate of E3 ubiquitin ligase ligand + Linker is Thalidomide-pyrrolidine-C-piperidine-Ph-NH2 (HY-168304). NX-2127 inhibits proliferation of BTK ^C481S mutant TMD8 cells, more effectively than Ibrutinib (HY-10997). NX-2127 catalyzes the degradation of Ikaros (IKZF1) and Aiolos (IKZF3) with of 25 nM and 54 nM, respectively. NX-2127 stimulates T cell activation and increases IL-2 production in primary human T Cells .

Cat. No.	Product Name	Chemical Structure

HY-10997S

Ibrutinib-d5
Ibrutinib-d₅ is a deuterium labeled Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor[1].

HY-100659S

*Dihydrodiol-Ibrutinib-d5*
Dihydrodiol-Ibrutinib-d5 is the deuterium labeled Dihydrodiol-Ibrutinib (HY-100659). Dihydrodiol-Ibrutinib is a dihydrodiol active metabolite of Ibrutinib (HY-10997), has inhibitory activity towards BTK approximately 15 times lower than that of ibrutinib .

Cat. No.	Product Name		Classification

HY-130481

Propargyl-PEG4-acid		PROTAC Synthesis Alkynes
Propargyl-PEG4-acid is a PEG-based PROTAC linker can be used in the synthesis of BTK-IAP PROTACs Ibrutinib (HY-10997)-based PROTAC 2 and an analogue PROTAC 3. PROTAC 3 causes BTK degradation with a DC₅₀ of 200 nM in THP-1 cells . Propargyl-PEG4-acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-130504

Propargyl-PEG1-acid 1 Publications Verification		PROTAC Synthesis Alkynes
Propargyl-PEG1-acid is a PEG-based PROTAC linker can be used in the synthesis of BTK-CRBN PROTACs Ibrutinib(HY-10997)-based PROTAC 4 and PROTAC 5. PROTAC 5 causes the degradation of BTK and induces the degradation of CSK, LYN, and LAT2 at 10 μM . Propargyl-PEG1-acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.